Journal of Clinical Oncology, Vol 14, 2495-2503, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group

JL Finlay, S Goldman, MC Wong, M Cairo, J Garvin, C August, BH Cohen, P Stanley, RA Zimmerman, B Bostrom, JR Geyer, RE Harris, J Sanders, AJ Yates, JM Boyett and RJ Packer
Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

PURPOSE: This study was designed to determine the toxicity, radiographic response rate, and outcome following high-dose thiotepa, etoposide, and autologous bone marrow rescue (ABMR) for young patients with recurrent malignant brain tumors. METHODS: Eligibility criteria required adequate renal, hepatic, and pulmonary function, and no bone marrow infiltration. Thiotepa 300 mg/m2 and etoposide 500 mg/ m2 were infused on 3 consecutive days, and autologous bone marrow was infused 72 hours following chemotherapy. RESULTS: Forty-five patients with recurrent high-grade brain tumors, aged 8 months to 36 years (median, 8 years), were treated. Seven patients (16%) died of treatment-related toxicities within 56 days of marrow reinfusion. Delayed platelet engraftment occurred in 44% of patients who survived beyond day 56. Of 35 patients with radiographically measurable disease who survived at least 28 days following ABMR, there were two complete responses (CRs) and six partial responses (PRs), for an overall response (CRs plus PRs) rate of 23% (SE = 7%). Objective responses were observed in four of 14 assessable patients with high-grade glioma and in two of six with primitive neuroectodermal tumors (PNETs)/ medulloblastoma. Survival was significantly improved in patients treated with minimal residual disease (P < .0005). Five of 18 patients (28%) with high-grade gliomas remain free of disease at 39+, 44+, 49+, 52+, and 59+ months post-ABMR. CONCLUSION: The combination of high-dose thiotepa and etoposide has activity against a variety of recurrent childhood brain tumors. These results merit further evaluation in children and young adults with both recurrent and newly diagnosed high-grade brain tumors.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. F. Pollack, R. I. Jakacki, S. M. Blaney, M. L. Hancock, M. W. Kieran, P. Phillips, L. E. Kun, H. Friedman, R. Packer, A. Banerjee, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report Neuro-oncol, April 1, 2007; 9(2): 145 - 160. [Abstract] [Full Text] [PDF]

				D. S. Ziegler, R. J. Cohn, G. McCowage, F. Alvaro, C. Oswald, R. Mrongovius, L. White, and for the Australian and New Zealand Children's Canc Efficacy of vincristine and etoposide with escalating cyclophosphamide in poor-prognosis pediatric brain tumors Neuro-oncol, January 1, 2006; 8(1): 53 - 59. [Abstract] [Full Text] [PDF]

				M. Massimino, L. Gandola, R. Luksch, F. Spreafico, D. Riva, C. Solero, F. Giangaspero, F. Locatelli, M. Podda, F. Bozzi, et al. Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma Neuro-oncol, January 1, 2005; 7(1): 41 - 48. [Abstract] [PDF]

				S. N. Chi, S. L. Gardner, A. S. Levy, E. A. Knopp, D. C. Miller, J. H. Wisoff, H. L. Weiner, and J. L. Finlay Feasibility and Response to Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma J. Clin. Oncol., December 15, 2004; 22(24): 4881 - 4887. [Abstract] [Full Text] [PDF]

				A. Broniscer and A. Gajjar Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist Oncologist, April 1, 2004; 9(2): 197 - 206. [Abstract] [Full Text] [PDF]

				C. D. Turner, S. Gururangan, J. Eastwood, K. Bottom, M. Watral, R. Beason, R. E. McLendon, A. H. Friedman, S. Tourt-Uhlig, L. L. Miller, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience Neuro-oncol, April 1, 2002; 4(2): 102 - 108. [Abstract] [PDF]

				D. Strother, D. Ashley, S. J. Kellie, A. Patel, D. Jones-Wallace, S. Thompson, R. Heideman, E. Benaim, R. Krance, L. Bowman, et al. Feasibility of Four Consecutive High-Dose Chemotherapy Cycles With Stem-Cell Rescue for Patients With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor After Craniospinal Radiotherapy: Results of a Collaborative Study J. Clin. Oncol., May 15, 2001; 19(10): 2696 - 2704. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, C. P. Anderson, W. A. Bleyer, J. G. Cairncross, T. Cloughesy, S. L. Eck, P. Guastadisegni, W. A. Hall, L. L. Muldoon, S. J. Patel, et al. Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium Neuro-oncol, January 1, 2001; 3(1): 46 - 54. [Abstract] [PDF]

				R. J. Packer, P. Cogen, G. Vezina, and L. B. Rorke Medulloblastoma: Clinical and biologic aspects Neuro-oncol, July 1, 1999; 1(3): 232 - 250. [Abstract] [PDF]

				D. A Walker, J. A G Punt, and M. Sokal Clinical management of brain stem glioma Arch. Dis. Child., June 1, 1999; 80(6): 558 - 564. [Full Text]

				R. J. Packer Brain Tumors in Children Arch Neurol, April 1, 1999; 56(4): 421 - 425. [Abstract] [Full Text] [PDF]

				V. A. Levin Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are heading Neuro-oncol, January 1, 1999; 1(1): 69 - 80. [Abstract] [PDF]